Poolbeg Pharma (LON:POLB) Earns House Stock Rating from Shore Capital

Poolbeg Pharma (LON:POLB)‘s stock had its “house stock” rating restated by research analysts at Shore Capital in a report issued on Thursday,London Stock Exchange reports.

Poolbeg Pharma Stock Performance

Shares of POLB stock traded up GBX 0.12 during midday trading on Thursday, reaching GBX 3.80. 2,614,594 shares of the company were exchanged, compared to its average volume of 1,916,581. The company’s 50 day moving average price is GBX 3.77 and its two-hundred day moving average price is GBX 3.35. The company has a market cap of £26.49 million, a P/E ratio of -3.33 and a beta of 2.11. Poolbeg Pharma has a 12 month low of GBX 2.25 and a 12 month high of GBX 7.80.

Poolbeg Pharma (LON:POLB) last announced its earnings results on Monday, September 29th. The company reported GBX (0.43) EPS for the quarter. As a group, sell-side analysts predict that Poolbeg Pharma will post -0.68 earnings per share for the current year.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).